Taken together, these data suggest that, due to different CPEB4 levels, CSAG2 expression is differentially regulated by CPEB4-mediated translational control in paclitaxel-resistant ovarian cancer cells and recurrent ovarian tumors compared with their counterparts, which leads to CSAG2 accumulation in resistant cells. Here, CPEB4 is linked to ovarian neoplasm.